Peter Willeke

Summary

Country: Germany

Publications

  1. ncbi Interleukin 1beta and tumour necrosis factor alpha secreting cells are increased in the peripheral blood of patients with primary Sjögren's syndrome
    P Willeke
    Department of Medicine B, Westphalian Wilhelms University, Muenster, Germany
    Ann Rheum Dis 62:359-62. 2003
  2. ncbi Increased frequency of GM-CSF secreting PBMC in patients with active systemic lupus erythematosus can be reduced by immunoadsorption
    P Willeke
    Department of Medicine B, Westphalian Wilhelms University, Muenster, Germany
    Lupus 13:257-62. 2004
  3. ncbi Emerging treatment strategies and potential therapeutic targets in primary Sjögren's syndrome
    Heidemarie Becker
    Department of Medicine D, University of Muenster, Muenster, Germany
    Inflamm Allergy Drug Targets 9:10-9. 2010
  4. ncbi [Patient/rheumatologist evaluation of infusion treatment for rheumatoid arthritis]
    P Willeke
    Sektion Rheumatologie und Klinische Immunologie Medizinische Klinik und Polilklinik D, Universitatsklinikum Munster, Munster, Deutschland
    Z Rheumatol 70:232-4, 236-8. 2011
  5. ncbi Increased serum levels of macrophage migration inhibitory factor in patients with primary Sjögren's syndrome
    Peter Willeke
    Department of Medicine B, Muenster University Hospital, Albert Schweitzer Strasse 33, 48129 Muenster, Germany
    Arthritis Res Ther 9:R43. 2007
  6. ncbi Mycophenolate sodium treatment in patients with primary Sjögren syndrome: a pilot trial
    Peter Willeke
    Department of Medicine B, Muenster University Hospital, Albert Schweitzer Street 33, D 48129 Muenster, Germany
    Arthritis Res Ther 9:R115. 2007
  7. ncbi Interferon-gamma is increased in patients with primary Sjogren's syndrome and Raynaud's phenomenon
    Peter Willeke
    Department of Medicine B, Muenster University Hospital, Muenster, Germany
    Semin Arthritis Rheum 39:197-202. 2009
  8. ncbi The role of interleukin-10 promoter polymorphisms in primary Sjogren's syndrome
    P Willeke
    Department of Medicine B, Muenster University Hospital, Muenster, Germany
    Scand J Rheumatol 37:293-9. 2008
  9. ncbi Concomitant reduction of disease activity and IL-10 secreting peripheral blood mononuclear cells during immunoadsorption in patients with active systenic lupus erythematosus
    Peter Willeke
    Department of Medicine B, Westphalian Wilhelms University, Munster, Germany
    Cell Mol Biol (Noisy-le-grand) 48:323-9. 2002
  10. ncbi Ischaemic colitis mimicking inflammatory bowel disease in a young adult receiving oral anticoagulation
    Peter Willeke
    Department of Medicine B, Muenster University Hospital, Germany
    Scand J Gastroenterol 40:878-80. 2005

Detail Information

Publications22

  1. ncbi Interleukin 1beta and tumour necrosis factor alpha secreting cells are increased in the peripheral blood of patients with primary Sjögren's syndrome
    P Willeke
    Department of Medicine B, Westphalian Wilhelms University, Muenster, Germany
    Ann Rheum Dis 62:359-62. 2003
    ..To study systemic alterations of cytokine secreting peripheral blood mononuclear cells (PBMC) in primary Sjögren's syndrome (pSS) and their relation to common clinical and immunological manifestations of this disease...
  2. ncbi Increased frequency of GM-CSF secreting PBMC in patients with active systemic lupus erythematosus can be reduced by immunoadsorption
    P Willeke
    Department of Medicine B, Westphalian Wilhelms University, Muenster, Germany
    Lupus 13:257-62. 2004
    ..The impaired immunity can be modulated by IA. Thus IA may prove an immunomodulatory therapeutic option in addition to the mere depletion of anti-dsDNA autoantibodies...
  3. ncbi Emerging treatment strategies and potential therapeutic targets in primary Sjögren's syndrome
    Heidemarie Becker
    Department of Medicine D, University of Muenster, Muenster, Germany
    Inflamm Allergy Drug Targets 9:10-9. 2010
    ..Since efficacy of many agents depends on the presence of residual functional glandular tissue, future studies should focus on patients with recent onset of pSS...
  4. ncbi [Patient/rheumatologist evaluation of infusion treatment for rheumatoid arthritis]
    P Willeke
    Sektion Rheumatologie und Klinische Immunologie Medizinische Klinik und Polilklinik D, Universitatsklinikum Munster, Munster, Deutschland
    Z Rheumatol 70:232-4, 236-8. 2011
    ..c.) or via intravenous (i.v.) infusion with variable intervals depending on the drug. This investigation aims to identify the preferences and concerns of affected patients and their physicians...
  5. ncbi Increased serum levels of macrophage migration inhibitory factor in patients with primary Sjögren's syndrome
    Peter Willeke
    Department of Medicine B, Muenster University Hospital, Albert Schweitzer Strasse 33, 48129 Muenster, Germany
    Arthritis Res Ther 9:R43. 2007
    ..MIF may contribute to B-cell hyperactivity indicated by hypergammaglobulinemia. The inverse relationship of IL-10 and MIF suggests that IL-10 works as an antagonist of MIF in pSS...
  6. ncbi Mycophenolate sodium treatment in patients with primary Sjögren syndrome: a pilot trial
    Peter Willeke
    Department of Medicine B, Muenster University Hospital, Albert Schweitzer Street 33, D 48129 Muenster, Germany
    Arthritis Res Ther 9:R115. 2007
    ..Further investigations about the efficacy and safety of MPS in pSS have to be performed in larger numbers of patients...
  7. ncbi Interferon-gamma is increased in patients with primary Sjogren's syndrome and Raynaud's phenomenon
    Peter Willeke
    Department of Medicine B, Muenster University Hospital, Muenster, Germany
    Semin Arthritis Rheum 39:197-202. 2009
    ..Since increased interferon-gamma (INF-gamma) has been associated with RP, we also compared the INF-gamma production in pSS patients with or without RP...
  8. ncbi The role of interleukin-10 promoter polymorphisms in primary Sjogren's syndrome
    P Willeke
    Department of Medicine B, Muenster University Hospital, Muenster, Germany
    Scand J Rheumatol 37:293-9. 2008
    ..To determine the impact of a broad spectrum of different polymorphisms within the interleukin-10 (IL-10) promoter gene on disease susceptibility to primary Sjogren's syndrome (pSS), clinical manifestations, and autoantibody production...
  9. ncbi Concomitant reduction of disease activity and IL-10 secreting peripheral blood mononuclear cells during immunoadsorption in patients with active systenic lupus erythematosus
    Peter Willeke
    Department of Medicine B, Westphalian Wilhelms University, Munster, Germany
    Cell Mol Biol (Noisy-le-grand) 48:323-9. 2002
    ..The production of anti-ds-DNA antibodies and IL-10 are interdependent. Thus we conclude that IA is beneficial in SLE by depletion of these pathogenic antibodies which may lead to a reduced IL-10 secretion in vivo...
  10. ncbi Ischaemic colitis mimicking inflammatory bowel disease in a young adult receiving oral anticoagulation
    Peter Willeke
    Department of Medicine B, Muenster University Hospital, Germany
    Scand J Gastroenterol 40:878-80. 2005
    ..We present a case of a young man with known factor-V-Leiden mutation in whom IC developed during effective therapy with oral anticoagulants, presenting with symptoms and endoscopic findings suggestive of inflammatory bowel disease...
  11. ncbi Clinical utility of the anti-CCP assay: experiences with 700 patients
    Ulrich Sauerland
    Department of Medicine B, , Albert-Schweitzer-Strasse 33, , Germany
    Ann N Y Acad Sci 1050:314-8. 2005
    ..Anti-CCP also helps to diagnose other inflammatory and noninflammatory diseases (especially connective tissue diseases) by reducing the rate of false-positive results in comparison with RF...
  12. ncbi Macrophage migration inhibitory factor may contribute to vasculopathy in systemic sclerosis
    Heidemarie Becker
    Department of Medicine B, University of Muenster, Albert Schweitzer Str 33, 48129, Muenster, Germany
    Clin Rheumatol 27:1307-11. 2008
    ..MIF levels were not significantly different in patients with and without macrovascular disease of the peripheral arteries. The results suggest that MIF might contribute to inflammation and vasculopathy in SSc...
  13. ncbi Differentiation of RNP- and SM-antibody subsets in SLE and MCTD patients by a new ELISA using recombinant antigens
    Markus Gaubitz
    Department of Medicine B, University of Munster, Germany
    Cell Mol Biol (Noisy-le-grand) 48:317-21. 2002
    ..In SLE and MCTD, determination of subsets of antibodies against Ul-snRNP-68 kDa and Sm-complex allows a differentiation of patient subgroups with more definite diagnoses and potential prognostic impact...
  14. ncbi [Leg ulcer in mixed connective tissue disease. Resolution during sitaxsentan therapy]
    H Becker
    Medizinische Klinik und Poliklinik D, Universitatsklinikum Munster, Albert Schweitzer Str 33, 48149 Munster
    Z Rheumatol 68:154-6. 2009
    ..In addition, severity of RP ameliorated markedly. Further evaluation of sitaxsentan in patients with connective tissue diseases suffering from ischemic skin ulcers is required...
  15. ncbi Clinical and immunological characteristics of patients with Sjögren's syndrome in relation to alpha-fodrin antibodies
    P Willeke
    Department of Medicine B, Muenster University Hospital, Muenster, Germany
    Rheumatology (Oxford) 46:479-83. 2007
    ..To analyse the prevalence of alpha-fodrin antibodies in patients with primary (pSS) and secondary Sjögren's syndrome (sSS) and the relation to clinical, serological and immunological features...
  16. ncbi Extended haplotype analysis reveals an association of TNF polymorphisms with susceptibility to systemic lupus erythematosus beyond HLA-DR3
    H Schotte
    Department of Medicine B, Munster University Hospital, Germany
    Scand J Rheumatol 34:114-21. 2005
    ..To study the relative contribution of tumour necrosis factor (TNF) and HLA-DRB1 polymorphisms to the genetic susceptibility to systemic lupus erythematosus (SLE) via an extended haplotype analysis...
  17. ncbi [Four-year observation of etanercept therapy for rheumatoid arthritis in a single German center]
    H Schotte
    Medizinische Klinik und Poliklinik B, Universitatsklinikum Munster, Albert Schweitzer Str 33, 48129, Munster, Germany
    Z Rheumatol 64:265-73. 2005
    ..Severe adverse events were rare and not more frequent than expected. For the detection of uncommon or late occurring severe adverse events under the treatment with biologic agents, documentation in central registers should be encouraged...
  18. ncbi Interleukin 10 promoter microsatellite polymorphisms are associated with response to long term treatment with etanercept in patients with rheumatoid arthritis
    H Schotte
    Department of Medicine B, Munster University Hospital, Albert Schweitzer Str 33, D 48129 Munster, Germany
    Ann Rheum Dis 64:575-81. 2005
    ..To analyse the association of interleukin 10 (IL10) promoter polymorphisms, which have been shown to be related to IL10 secretion capacity, with the response to long term treatment with etanercept in patients with rheumatoid arthritis (RA)...
  19. ncbi Interleukin-10 promoter microsatellite polymorphisms in systemic lupus erythematosus: association with the anti-Sm immune response
    H Schotte
    Medizinische Klinik, Universitatsklinikum Munster, Germany
    Rheumatology (Oxford) 43:1357-63. 2004
    ..We analysed the association of IL-10 promoter microsatellite polymorphisms with disease susceptibility and manifestations in German Caucasian patients with SLE...
  20. ncbi Long-term treatment with etanercept significantly reduces the number of proinflammatory cytokine-secreting peripheral blood mononuclear cells in patients with rheumatoid arthritis
    H Schotte
    Medizinische Klinik, Universitatsklinikum Munster, Germany
    Rheumatology (Oxford) 43:960-4. 2004
    ....
  21. ncbi The transforming growth factor-beta1 gene polymorphism (G915C) is not associated with systemic lupus erythematosus
    H Schotte
    Medizinische Klinik und Poliklinik B, Universitatsklinikum, Munster, Germany
    Lupus 12:86-92. 2003
    ..Further studies are needed to corroborate the pathogenic role of TGF-beta1 in SLE patients and to identify the precise genetic elements controlling its production...
  22. ncbi Cat scratch disease (bartonellosis) mimicking an SLE flare
    M Gaubitz
    Department of Medicine, University of Munster, Germany
    Lupus 10:883-5. 2001
    ..This tentative diagnosis was confirmed serologically. Under clarithromycin treatment the patient rapidly responded and her temperature dropped within 2 days...